Symptom correlates of global measures of severity in schizophrenia

Comprehensive Psychiatry

Volumn 40, Issue 6, 1999, Pages 458-461

  Goldman, Mona ^a   DeQuardo, John R ^a   Tandon, Rajiv ^a   Taylor, Stephan F ^a   Jibson, Michael ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGITATION; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; OUTCOMES RESEARCH; RATING SCALE; SCHIZOIDISM; SCHIZOPHRENIA; SYMPTOM;

EID: 0032696577     PISSN: 0010440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-440X(99)90090-1     Document Type: Article

References (15)

1. Overall JE, Gorham DR. Brief Psychiatric Rating Scale (BPRS). Psychol Rep 1962;10:799-812.
2. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale for Schizophrenia. Schizophr Bull 1987;13:261-276.
3. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa Press, 1983.
4. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education and Welfare, 1976.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Ed. 3. Rev. Washington, DC: American Psychiatric Association, 1987.
6. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:1825-1835.
7. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465.
8. Davis KL, Thai LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, et al. The Tacrine Collaborative Study Group: a double-blind placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992;327:1253-1259.
9. Mayerhoff DI, Loebel AD, Alvir JMJ, Szymanski SR, Geisler SH, Boernstein M, et al. The deficit state in first-episode schizophrenia. Am J Psychiatry 1994;151:1417-1422.
10. Spitzer RL, Williams JBW, Gibbon M, First MD. Structured Clinical Interview for DSM-III-R-Patient Version (SCID-P). New York, NY: Biometrics Research Department, New York State Psychiatric Institute, 1988.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Ed. 4. Washington, DC: American Psychiatric Association, 1994.
12. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
13. Tandon R, Ribeiro SCM, DeQuardo JR, Goldman R, Goodson J, Greden JF. Covariance of positive or negative symptoms during neuroleptic treatment in schizophrenia: a replication. Biol Psychiatry 1993;34:495-497.
14. Wernicke JF, Dunlop SR, Dornseif BE, Zerbe RL. Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull 1987;23:164-168.
15. Hamilton M. Development of a scale for primary depressive illness. Br J Soc Clin Psychol 1960;6:278-296.